Insurers,
underwrite on real biomarkers, not a form.
Population and preventive screening at a lower cost per result, return-rate optimisation, and underwriting and risk insight from real biomarkers (collected at home, analysed in accredited laboratories).
Screening at scale is expensive.
Population and preventive screening (and the biomarker step in underwriting) depend on getting a clinical sample from a large group of people. When every sample needs a clinic visit, a phlebotomist and a cold chain, the cost per result is high and participation drops: the people who most affect your risk pool are often the least likely to show up. Self-reported health and proxy data only go so far.
Biomarkers at the door.
A neutral platform of regulated kits, clinical-grade logistics and accredited labs lets you collect real biomarkers from a population at home, at a materially lower cost per result.
Samples return to ISO 15189-accredited laboratories (we integrate labs and never compete with them, and the platform is GDPR-native by design). See the lab network →
From population to result.
Low-cost, ambient-stable kits ship at scale to the population in your programme, identity-matched and ordered through one integration, with your partner reaching the individual, not us.
People self-collect at home and return the sample under documented chain of custody. Dried and buffered formats travel ambient-stable (no refrigeration) with tracked returns to lift completion.
An accredited laboratory runs the assay; clean, structured results return through the same integration for screening outcomes or underwriting workflows.
Built for scale.
The formats that make population programmes affordable (low-cost, ambient-stable, no cold chain) on one platform into accredited labs.
Real results, handled properly.
Remote, patient-collected screening is validated and published (from at-home HbA1c to population programmes) and published programmes report high sample-return compliance. Results come from ISO 15189-accredited laboratories under documented chain of custody, and the platform is GDPR-native, with consent and privacy designed in. Humans Nexus does not diagnose or give medical advice and never sells to individuals directly, we provide the regulated infrastructure; the result is the laboratory’s.
Good to know.
How does this lower cost per result?
Removing the clinic visit, the phlebotomist and (for ambient-stable formats) the cold chain takes the most expensive parts out of population screening. Low-cost dried and buffered kits mail at scale and return without refrigeration. See logistics →
How do you improve return rates?
Identity-matched kits, clear at-home guidance and tracked returns are designed to lift completion. Published remote programmes report high sample-return compliance.
How is participant data handled?
The platform is GDPR-native, with consent and privacy designed in. Results come from accredited laboratories under documented chain of custody. Your partner reaches the individual; we provide the infrastructure and never sell directly.
Can results feed underwriting and risk workflows?
Yes. Clean, structured results return through one integration, so real-biomarker data can flow into screening outcomes or underwriting and risk-insight workflows. See Pulse →
Do you diagnose or advise?
No. Humans Nexus does not diagnose or give medical advice. We deliver structured results from the accredited laboratory; clinical interpretation stays with the appropriate clinical or actuarial process.
Screen a population, at home.
Talk to us about lower-cost, at-home screening and real-biomarker insight for your programme.